For example, compounds that enhance the enzymatic activity or increase the expression of ATP13A2 enzyme, a protein associated with Parkinson’s disease 9 (PARK9), would increase the clearance of accumulated α-synuclein via the lysosomal pathways [67–70]. This evidence concerns the gene ATP13A2 and parkinsonism due to ATP13A2 deficiency.